Court rules in Pfizer's favour in Norvasc patent case |
|
|
|
Published
:
Thu, 01 Feb 2007 11:13
|
LONDON (AFX) - Pfizer Inc said the federal district court in the Eastern District of Virginia has ruled that Synthon IP obtained, 'by inequitable conduct', two U.S. patents alleged to cover a process and an intermediate compound used to make the active ingredient in Pfizer's widely-prescribed hypertension drug Norvasc.Pfizer said the court found that Synthon had knowingly failed to disclose to the US Patent Office Pfizer publications and other information it had in its possession that described the process Synthon sought to patent.Pfizer said it intends to seek attorneys' fees from Synthon. The case may be appealed.Synthon had asserted that Pfizer's process for manufacturing Norvasc -- a process Pfizer had not only published but has been using for 15 years -- infringed Synthon patents issued in 2003 and 2005.In August of last year, a jury unanimously ruled that one of those patents was not infringed by Pfizer and was invalid on multiple grounds, principally because it was based on Pfizer's prior published work.Norvasc is Pfizer's second-best-selling product.Synthon is a subsidiary of Dutch company Synthon BVnewsdesk@afxnews.comrwCOPYRIGHTCopyright AFX News Limited 2006. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
1492.38 |
+42.58 (
3.01 %)
|
| SYMBOL (
2008-12-03 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
1411.00 |
+64.00 (
4.79 %)
|
| SYMBOL (
2008-12-03 )
|
| LAST |
CHANGE
|
| SYMBOL (
2008-12-03 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Pfizer to appeal Canadian court's denial of its Lipitor calcium salt patent suit 